Pacira Pharmaceuticals (PCRX) Set to Announce Earnings on Wednesday

Pacira Pharmaceuticals (NASDAQ:PCRX) will be releasing its earnings data before the market opens on Wednesday, May 2nd. Analysts expect Pacira Pharmaceuticals to post earnings of $0.02 per share for the quarter.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The company had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. During the same quarter in the previous year, the company earned $0.09 earnings per share. Pacira Pharmaceuticals’s quarterly revenue was up 8.5% on a year-over-year basis. On average, analysts expect Pacira Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ PCRX opened at $35.30 on Wednesday. Pacira Pharmaceuticals has a 1 year low of $26.95 and a 1 year high of $52.47. The company has a debt-to-equity ratio of 0.99, a quick ratio of 6.22 and a current ratio of 6.96. The stock has a market cap of $1,465.62, a P/E ratio of -60.86 and a beta of 1.77.

A number of brokerages have weighed in on PCRX. Oppenheimer restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, March 1st. Royal Bank of Canada set a $44.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 1st. ValuEngine upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 9th. BidaskClub cut shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Finally, Wedbush restated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $44.35.

COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals (PCRX) Set to Announce Earnings on Wednesday” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://weekherald.com/2018/04/25/pacira-pharmaceuticals-pcrx-set-to-announce-earnings-on-wednesday.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply